QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended March 31, 2010
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE TRANSITION PERIOD FROM TO .
Commission File Number 0-14942
PRO-DEX, INC.
(Exact name of Registrant as specified in its charter)
Colorado
84-1261240
(State or Other Jurisdiction of
(IRS Employer Identification No.)
Incorporation or Organization)
2361 McGaw Avenue, Irvine, California 92614
(Address of Principal Executive Offices)
Registrant's telephone number: 949-769-3200
Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past ninety days. Yes [X] No [ ]
Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes [] No [ ]
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company under Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [ X ]
Indicate whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]
Indicate the number of shares outstanding of each of the Registrant’s classes of Common Stock as of the latest practicable date: 9,753,671 shares of Common Stock, no par value, as of April 28, 2010.
INDEX
Pro-Dex, Inc.
Part I. Financial Information
2
Item 1. Financial Statements:
Condensed consolidated balance sheets – June 30, 2009 and March 31, 2010 (unaudited)
Condensed consolidated statements of operations (unaudited) – Three months ended March 31, 2010 and 2009
3
Condensed consolidated statements of operations (unaudited) – Nine months ended March 31, 2010 and 2009
4
Condensed consolidated statements of cash flows (unaudited) – Nine months ended March 31, 2010 and 2009
5
Notes to condensed consolidated financial statements (unaudited) – March 31, 2010
6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
15
Item 3. Quantitative and Qualitative Disclosures About Market Risk
26
Item 4T. Controls and Procedures
Part II. Other Information
27
Item 1. Legal Proceedings
Item 1A. Risk Factors
28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
29
Item 3. Defaults Upon Senior Securities
Item 4. (Removed and Reserved).
Item 5. Other Information
Item 6. Exhibits
Signatures
30
1
Item 1. Financial Statements
PRO-DEX, INC. and SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
3/31/2010
6/30/2009
ASSETS
Current assets:
Cash and cash equivalents
$
3,352,000
1,124,000
Accounts receivable, net of allowance for doubtful accounts
of $51,000 at 03/31/2010 and $52,000 at 6/30/09
2,776,000
2,515,000
Other Current Receivables
-
16,000
Inventories
2,856,000
3,365,000
Prepaid expenses
232,000
117,000
Prepaid income taxes
118,000
Total current assets
9,216,000
7,255,000
Property, plant, equipment and leasehold improvements, net
5,551,000
5,981,000
Other assets:
Goodwill
2,997,000
Intangibles - Patents, net
147,000
Other
87,000
Total other assets
3,084,000
3,231,000
Total assets
17,851,000
16,467,000
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
829,000
827,000
Accrued expenses
2,069,000
1,394,000
Income taxes payable
53,000
Current Portion of T.I. Loan
400,000
Current portion of real estate loan
34,000
33,000
Total current liabilities
3,332,000
2,707,000
Long-term liabilities:
Notes Payable - T.I. Loan
1,067,000
1,367,000
Real estate loan
1,502,000
1,528,000
Deferred income taxes
188,000
171,000
Deferred rent
247,000
212,000
Total long-term liabilities
3,004,000
3,278,000
Total liabilities
6,336,000
5,985,000
Commitments and contingencies
Shareholders' equity:
Common shares; no par value; 50,000,000 shares authorized;
9,680,149 shares issued and outstanding Mar 31, 2010
9,668,671 shares issued and outstanding June 30, 2009
16,670,000
16,574,000
Accumulated deficit
(5,155,000)
(6,092,000)
Total shareholders' equity
11,515,000
10,482,000
Total liabilities and shareholders' equity
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three months ended March 31 (unaudited)
2010
2009
Net sales
6,161,000
4,608,000
Cost of sales
3,869,000
3,497,000
Gross profit
2,292,000
1,111,000
Operating expenses:
Selling expense
383,000
315,000
General and administrative expenses
886,000
781,000
Impairment of intangible asset
997,000
Research and development costs
614,000
686,000
Total operating expenses
1,883,000
2,779,000
Income (Loss) from operations
409,000
(1,668,000)
Other income (expense):
Royalty income
40,000
Interest expense
(50,000)
(56,000)
Total
(10,000)
Income (Loss) before provision (benefit) for income taxes
399,000
(1,724,000)
Provision for income taxes
225,000
1,287,000
Net Income (Loss)
174,000
(3,011,000)
Net Income (Loss) per share:
Basic
0.02
(0.31)
Diluted
Weighted average shares outstanding - basic
9,703,615
9,684,071
Weighted average shares outstanding - diluted
9,721,693
See notes to condensed consolidated financial statements.
Nine months ended March 31 (unaudited)
17,490,000
15,501,000
11,324,000
10,703,000
6,166,000
4,798,000
1,025,000
988,000
2,412,000
2,461,000
140,000
1,811,000
2,083,000
5,388,000
6,529,000
Income (loss) from operations
778,000
(1,731,000)
44,000
9,000
(154,000)
(176,000)
(110,000)
(167,000)
Income (Loss) before (benefit) Provision for income taxes
668,000
(1,898,000)
(Benefit) Provision for income taxes
(269,000)
1,149,000
Net Income (loss)
937,000
(3,047,000)
Net income (loss) per share:
0.10
9,680,149
9,722,408
9,699,138
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Cash Flows from Operating Activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
546,000
611,000
Stock based compensation
96,000
129,000
Recovery of doubtful accounts
(1,000)
(35,000)
Increase (Decrease) in deferred taxes
(923,000)
Increase in deferred tax allowance
1,960,000
Changes in:
(Increase) Decrease in accounts receivable
(245,000)
1,043,000
Decrease in inventories
509,000
1,347,000
(Increase) Decrease in prepaid expenses
(115,000)
55,000
(Increase) in other assets
(20,000)
Increase (Decrease) in accounts payable and accrued expenses
712,000
(1,341,000)
(Decrease) in income taxes payable
(36,000)
64,000
Net Cash provided by Operating Activities
2,661,000
840,000
Cash Flows From Investing Activities:
Purchases of equipment and leasehold improvements
(109,000)
(181,000)
Net Cash used in Investing Activities
Cash Flows from Financing Activities:
Net (payments) on line of credit
(2,000,000)
Principal (payments) on term note
(396,000)
Net Principal (Payments) borrowing on TI Loan
(300,000)
1,866,000
Principal (payments) on mortgage
(24,000)
(23,000)
Stock repurchases
(119,000)
Net Cash used by Financing Activities
(324,000)
(672,000)
Net increase (decrease) in Cash and Cash Equivalents
2,228,000
(13,000)
Cash and Cash Equivalents, beginning of period
517,000
Cash and Cash Equivalents, end of period
504,000
Supplemental Information
Cash payments for interest
157,000
178,000
Cash payments for income taxes
PRO-DEX, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements of Pro-Dex, Inc. (“we”, “us”, “our”, “Pro-Dex” or the "Company") have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-K. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the audited financial statements presented in our Annual Report on Form 10-K for the fiscal year ended June 30, 2009. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The results of operations for such interim periods are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2009.
NOTE 2. INVENTORIES
Inventories are stated at the lower of cost (the first-in, first-out method) or market and consist of the following:
March 31, 2010
June 30, 2009
Raw Materials
1,167,000
1,290,000
Work in process
557,000
867,000
Finished goods
1,132,000
1,208,000
Total inventories
NOTE 3. WARRANTY
The warranty reserve is based on historical costs of warranty repairs and expected future identifiable warranty expenses. As of March 31, 2010, within our accrued expenses, we carried a warranty reserve of $734,000 which was comprised of $686,000 for medical products, $8,000 for aerospace products and $40,000 for dental and industrial products. Warranty expenses are reflected in the financial statements in cost of sales (“COS”). Adjustments to pre-existing warranties are due to assumption changes resulting from updating the cost to repair and warranty return rates to the current estimated cost and return rates. The total warranty expense reflected in the COS for the quarter ended March 31, 2010 was $218,000 and for the nine-months ended March 31, 2010 was $586,000. The total warranty expense reflected in the COS for the quarter ended March 31, 2009 was $26,000 and for the nine-months ended March 31, 2009 was $184,000.
The warranty accrual and expenses for the three and nine-months ended March 31, 2010 and 2009 are presented below:
Three months Ended March 31,
Beginning Balance
649,000
685,000
Warranties issued during period
161,000
167,000
Adjustments to pre-existing warranties
due to assumption changes
57,000
(141,000)
Settlements (actual expenditures)
(133,000)
(132,000)
Ending Balance
734,000
579,000
Nine months Ended March 31,
518,000
861,000
538,000
524,000
48,000
(340,000)
(370,000)
(466,000)
NOTE 4. NET INCOME (LOSS) PER SHARE
The following table reconciles the weighted average shares outstanding for basic and diluted net income per share for the periods indicated.
Three Months Ended March 31,
Basic net income (loss) per common share:
Weighted average number of common shares outstanding
Basic net income (loss) per common share
Diluted net income (loss) per share:
Weighted average of common shares outstanding
Effect of potentially dilutive securities (options)
18,078
Weighted average number of common and shares - Diluted
Diluted net income (loss) per common share
Nine Months Ended March 31,
Net income (loss)
Basic net income per common share:
Diluted net income per share:
18,989
Potentially dilutive securities not included in the diluted loss per share calculation due to net losses from continuing operations and for options that have a strike price higher than the market price for our common stock (no intrinsic value) are as follows (unaudited):
Options to purchase common shares
415,500
1,032,691
Restricted Shares
50,993
Warrants to purchase common shares
59,993
Total potentially dilutive securities excluded due to no intrinsic value
1,143,677
7
29,715
Total potentially dilutive securities excluded due to net loss
1,111,989
1,222,975
NOTE 5. CREDIT FACILITIES
We have a credit facility with Wells Fargo Bank, N.A. (“Wells Fargo”) and a mortgage with Union Bank of California, N.A (“Union Bank”).
Wells Fargo Credit Facility
As of March 31, 2010, the Wells Fargo credit facility had two components:
a revolving Credit Line Note (“line of credit”) of up to $1,000,000 in borrowing availability, and
a Five year Term Note (the “TI Loan”) with an initial balance of $2,000,000, of which $1,466,667 was outstanding as of March 31, 2010.
If borrowings under the line of credit exceed $500,000, the maximum amount of borrowing is limited to the lesser of $1,000,000 or 70% of the eligible accounts receivable plus 40% of the eligible inventory. Its terms require monthly interest payments at either (i) the prime rate of interest (3.25% at March 31, 2010) plus 1.50%, or (ii) three-month LIBOR (0.292% at March 31, 2010) plus 2.50%, at our discretion, based on outstanding borrowings. The line of credit expires on November 1, 2010. We are charged an unused credit line fee of 1.5% per annum payable quarterly on the average balance of the line of credit that is not used. There was no outstanding balance under the credit line as of March 31, 2010. The total eligible additional borrowing capacity under the line of credit as of March 31, 2010 was $1,000,000.
The TI Loan had an initial balance of $2,000,000. The borrowings from this term commitment were used for construction of tenant improvements for our Irvine, California facility. Its terms require monthly principal and interest payments over the 60-month life of the loan, based on outstanding borrowings. The interest rate is fixed at 5.72% over the life of the loan. There was a $1,466,667 outstanding balance under the TI Loan as of March 31, 2010.
All assets of the Company except our Carson City land and building secure the outstanding borrowings under the Wells Fargo credit facility.
Union Bank Mortgage
In March 2006, we entered into a ten-year mortgage with Union Bank for $1,650,000. The principal balance of the mortgage bears interest at a fixed annual rate of 6.73%. Payments on the mortgage are $11,379 per month (based on a 25 year amortization), with the balance of $1,291,666 in principal due on April 1, 2016. The mortgage is secured by our Carson City land and building. There was $1,536,063 in principal outstanding under the mortgage as of March 31, 2010.
8
There are certain financial and non-financial covenants that the Company must meet to be in compliance with the terms of the Wells Fargo credit facility and mortgage with Union Bank. As of the quarter ended March 31, 2010, we were in compliance with the Wells Fargo and Union Bank covenants.
NOTE 6. INCOME TAXES
Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax assets. Such determination is based primarily on our historical taxable income, with some consideration given to our estimates of future taxable income by jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable. Due to cumulative taxable losses during the past three years, we recorded a $2,241,000 valuation allowance against our deferred tax assets in the year ended June 30, 2009.
As of March 31, 2010, the valuation allowance against our deferred tax assets is approximately $1,810,000. The change in valuation allowance is due primarily to realization of the Company's deferred tax asset for the federal net operating loss carryover generated in the year ended June 30, 2009. Federal legislation enacted on November 6, 2009 provided for a five year carry back of certain Net Operating Losses increasing the time period eligible to take the benefit of these losses from two years.
As of March 31, 2010, pursuant to ASC 740 (formerly FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes"), we have accrued $63,000 of unrecognized tax benefits related to state income tax matters that would reduce the Company’s income tax expense if recognized and would result in a corresponding decrease in the Company’s effective tax rate.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
Balance at July 1, 2009
Additions based on tax positions related to the current year
Additions for tax positions of prior years
Reductions for tax positions of prior years
Settlements
Balance at March 31, 2010
We recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense when applicable. As of March 31, 2010, there was no interest or penalties applicable to our unrecognized tax benefits since the Company has sufficient tax attributes available to fully offset any potential assessment of additional tax.
Pro-Dex and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions. We are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended June 30, 2007 through June 30, 2009. Our state income tax returns are open to audit under the statute of limitations for the years ended June 30, 2006 through June 30, 2009. We do not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.
9
NOTE 7. SHARE-BASED COMPENSATION
Share-based compensation pre-tax expense pursuant to ASC 718 (formerly SFAS 123(R)) was $25,000 and $42,000 for the three months and was $96,000 and $129,000 for the nine months ended March 31, 2010 and 2009, respectively, which were related to stock options and restricted stock grants. Share-based compensation expense reduced our results of operations as shown:
Three months ended March 31,
(unaudited)
Share-based compensation expense recognized:
General and administrative, options
6,000
13,000
General and administrative, restricted stock
19,000
29,000
Subtotal expense
25,000
42,000
Related deferred tax benefit
(9,000)
Decrease in net income
Decrease in basic earnings per share
0.00
Decrease in diluted earnings per share
Nine months ended March 31,
18,000
41,000
78,000
88,000
(33,000)
63,000
0.01
As of March 31, 2010, there was $17,000 of total unrecognized compensation cost related to 102,500 non-vested outstanding stock options with a per share weighted average value of $0.96. The unrecognized expense is anticipated to be recognized on a straight-line basis over a weighted average period of 0.6 years. The following is a summary of stock option activity in the nine months ending March 31, 2010 and 2009 (unaudited):
Weighted-
Average
Options
Shares
Exercise Price
Outstanding at beginning of fiscal year (7/1)
933,000
1.42
1,109,500
1.58
Granted
66,000
0.52
106,000
0.62
Exercised
Forfeited
(417,500)
1.43
(22,500)
1.92
Outstanding at end of period (3/31)
581,500
1.31
1,193,000
1.49
Exercisable at end of period (3/31)
479,000
1.39
1,019,500
1.56
Weighted-average fair value per
Option granted during the period
0.22
0.28
10
The following table summarizes information regarding options outstanding and options exercisable at March 31, 2010 (unaudited). The intrinsic value indicated on the table below is based on the stock price at March 31, 2010 of $0.51 per common share.
Options Outstanding
Options Exercisable
Aggregate
Range of
Number
Remaining
Exercise
Intrinsic
Outstanding
Contractual Life
Price
Value
$0.42 to $0.81
249,500
5.7 years
0.56
8,920
194,000
8,230
$1.00 to $1.56
182,000
6.3 years
135,000
1.37
$1.74 to $2.18
60,000
4.7 years
1.84
$2.55 to $3.30
90,000
5.3 years
2.89
Restricted Stock
The following is a summary of restricted share activity in the nine months ending March 31, 2010 and 2009 respectively (unaudited):
Weighted-Average
Restricted shares
85,000
1.38
170,000
Issued
(85,000)
As of March 31, 2010, there was no remaining unrecognized compensation cost related to non-vested outstanding restricted shares.
NOTE 8. MAJOR CUSTOMERS
We had two major customers (defined as a customer that represents greater than 10% of the Company’s total revenues) in the nine months ended March 31, 2010 and 2009.
Revenues
Accts. Rec.
Customer 1
3,727,000
269,000
3,070,000
720,000
Customer 2
6,584,000
869,000
4,509,000
527,000
We have been notified by Customer 2 that they are in the process of developing, and plan to eventually manufacture, their own surgical hand pieces which are functionally comparable to the two products currently provided by the Company. Pro-Dex has been the exclusive manufacturer of these products since they were developed.
11
The Customer has not provided firm transition dates or volumes due to the inherent uncertainty in the design, testing, and qualification process.
In March, 2010 the Company received purchase orders from this customer for production of the first product for quantities that would support the Customer’s historical consumption rates through the Company’s fourth quarter of fiscal year 2011. Because the Customer has stated it intends to build inventory, it has requested to take delivery of all of these hand pieces by the end of October 2010.
Regarding the second product, the customer’s original planning communicated in December 2009 was extended by six months through at least June 2011 and the Company received a purchase order for normal deliveries through February 2011, with a follow-on P.O. for the balance expected by us toward the end of this calendar year as indicated by the customer’s latest communication. The purchase orders for products one and two totaled $4.2 million. Additionally, the Customer indicated both in December 2009 and March 2010 that they intend to continue purchasing some portion of these products from the Company for up to three years to support existing customers with additional and replacement units of the same type and in specific geographic markets where regulatory registration for the replacement units requires an extended period of time.
The design and production of these products is quite technologically challenging, as such devices are exposed to extremely harsh surgical and sterilization conditions. A different large customer of the Company pursued a similar course of action several years ago and ultimately canceled its in-sourcing project, continuing its purchases from Pro-Dex. The Customer currently pursuing this course has indicated a high commitment to proceeding cautiously. Accordingly, the actual occurrence of, and certainly the specific timing of any transition is very difficult to estimate.
The Company intends to find additional business and reduce its operating costs as necessary to minimize the impact of a potential revenue reduction. In the event that the Customer's future purchases are reduced beyond the additional business won and the cost savings realized, the Company is likely to experience a material and adverse impact on its business.
The Company has no commitment from the Customer that it will update the Company with the status of its product development efforts and the Customer has no obligation to do so. Accordingly, the Company is unable to know or predict the status of the Customer's initiative on an ongoing basis. The name of the Customer is protected by a confidentiality agreement.
NOTE 9. COMMITMENTS AND CONTINGENCIES
Our manufacture and distribution of certain products involves a risk of legal action, and, from time to time, we are named as defendants in lawsuits. It is not reasonably possible to estimate the awards or damages, or the range of awards or damages, if any, we might incur in connection with such litigation. Other than the case pending with the Orange County Water District discussed below, management is not aware of any material actual, pending or threatened litigation at this time.
On June 23, 2008, the Orange County Water District (“OCWD”) filed a complaint in the Superior Court of the State of California in the County of Orange concerning remediation of alleged ground water contamination in the Orange County Groundwater South Basin; Orange County Water District v. Sabic Innovative Plastics U.S. LLC, et al., Case No. 00078246. The South Basin underlies parts of Santa Ana, California and adjacent cities. The complaint identifies 17 named defendants, including Pro-Dex, and also designates 400 unnamed Doe defendants. We moved out of this Santa Ana site in April, 2008 and have no remaining operations there. Since January 1, 2009, OCWD has named 11 additional defendants by multiple amendments to its complaint.
12
The complaint alleges that the defendants contaminated the South Basin with volatile organic chemicals (“VOCs”) and perchlorate through various activities at properties each defendant now controls or has controlled in the past. Through its lawsuit, the OCWD seeks compensatory relief for all its own remedial activities, and injunctive relief to compel the defendants to undertake remedial activities in general. The complaint does not, however, specify any remedial activities that the OCWD has undertaken to date or any remedial activities that it seeks any particular defendants to undertake. Moreover, from our investigation of OCWD’s remedial activities to date, we have determined that the OCWD is in the early stages of its remedial investigation for the South Basin groundwater contamination. In two recent Case Management Conferences before the court, OCWD has refused defendants’ request to designate a date by which it will disclose its proposed soil and groundwater cleanup remedies.
As noted above, 27 other entities are named defendants in this case along with Pro-Dex. While some are small businesses, others are larger corporations or their subsidiaries. Further, as this case progresses, the OCWD is likely to add at least a few more named defendants to the case from the 400 Doe defendants it has designated in the current complaint. In the indeterminable event that we would be held liable in the case, OCWD’s total recovery probably would be allocated among several defendants, each of which would pay only a proportionate share of that total recovery.
One of our past insurers has committed to pay most of our defense costs for the lawsuit, and has done so to date, while reserving its rights as to whether it will cover any damages awarded against us, or any settlement payment to which Pro-Dex agrees to resolve the lawsuit, under past policies issued to us for a three-year period, March 31, 1983 to March 31, 1986. The policies of these years have occurrence payment limits of $500,000.
Overall, the OCWD complaint remains vague, the OCWD is in an early stage of its remedial activities in the South Basin, the lawsuit is in the early stages of discovery, one of our insurers has committed to pay most defense costs and has reserved rights under one three-year set of policies and is continuing to consider extending coverage to us under other past policies, and any recovery the OCWD may gain through the lawsuit is likely to be allocated among several defendants. Therefore, our liabilities, as well as our costs of defending, monitoring and concluding our involvement in this case are uncertain, and those costs cannot now be estimated.
On February 3, 2010, the Company and Patrick Johnson, the Company's Executive Vice President and Chief Business Development Officer, entered into a Separation Agreement and General Release of All Claims (“Separation Agreement”) concerning the conclusion of Mr. Johnson's employment services with the Company effective as of February 5, 2010 (the “Separation Date”).
As part of the separation agreement, the Company will: (i) pay Mr. Johnson, over a period of six months beginning on the Separation Date, in regular installments, a gross amount equal to Mr. Johnson’s last regular bi-weekly salary until the total gross payments have reached the amount of $105,000, less applicable legal deductions and withholdings; (ii) provided Mr. Johnson elects coverage under the Company’s group health insurance program prior to the Separation Date, and makes a timely election for continued coverage pursuant to COBRA, pay the Company’s portion of the monthly premiums for such continued coverage under the Company’s group health insurance program for a period from the Separation Date through July 31, 2010, with continuing coverage thereafter at Mr. Johnson's election and sole expense, as available; and (iii) make available to Mr. Johnson the following Additional Contingent Separation Payment (“ACSP”), subject to the provisions of the Separation Agreement:
13
at any time between March 8, 2010, through August 7, 2010, Mr. Johnson shall be entitled to notify the Company in writing that he wishes to cause the Company to calculate and pay him all or a portion of the ACSP, in which event the Company:
(a) shall calculate the average closing price of its common stock for the five trading days immediately preceding the date of the receipt of Mr. Johnson’s written notice (the “Five Day Price”). If the Five Day Price is greater than $1.50, then $1.50 shall be used as the Five Day Price;
(b) shall, with respect to one or more such option grants as Mr. Johnson shall have identified in his written notice that were (i) previously held by Mr. Johnson under grant dates from June 30, 2001 through September 6, 2002, (ii) outstanding as of the Separation Date, and (iii) not exercised by Mr. Johnson between the Separation Date and March 7, 2010 (each a “Reference Grant”), subtract from the Five Day Price the strike (i.e., exercise) price of each Reference Grant identified in the written notice; and
(c) shall pay to Mr. Johnson an ACSP equal to the product of (i) amount arrived at in (b) above, multiplied by (ii) the total number of options that are contained in each Reference Grant specified by Mr. Johnson in his written notice;
the maximum aggregate ACSP shall in no event exceed $117,125;
Mr. Johnson’s eligibility to request payment of the ACSP is further subject to the following provisions: (a) at no time from the Separation Date through August 7, 2010, shall Mr. Johnson take any action with a purpose of influencing the stock price of the Company’s common stock, and (b) at no time from March 8, 2010, through August 7, 2010, shall Mr. Johnson trade, for himself or anyone acting in concert with him, in the stock, options or other equity of the Company; and
the numbers and amount used in calculating the ACSP are to be proportionately adjusted in the event of any reverse or forward stock split or other adjustment to the capital structure of the Company.
At the closing NASDAQ market price of $0.51 as of March 31, 2010, there is no positive value for the ACSP.
Reference Grant
Strike Price
112,500
0.81
75,000
1.06
100,000
287,500
NOTE 10. FAIR VALUE MEASUREMENTS
Fair Value Measurements — Effective July 1, 2008, the Company adopted ASC 820 (formerly Statement of Financial Accounting Standards No. 157, “Fair Value Measurements”) for financial assets and liabilities measured at fair value on a recurring basis. ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. In addition to expanding the disclosures surrounding fair value measurements, ASC 820 indicates that fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
14
Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.
The following valuation methodology was used for the Company’s assets to measure fair value at March 31, 2010:
Cash and cash equivalents: The carrying value of cash and cash equivalents is considered to be representative of their fair values based on the short term nature of these instruments. As such these investments are classified within level 1 of the valuation hierarchy.
Although the methods above may produce a fair value calculation that may not be indicative of the net realizable value or reflective of future fair values, the Company believes its valuation methods are appropriate.
The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
The following fair value hierarchy table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2010 (unaudited):
Description
Level 1
Level 2
Level 3
NOTE 11. SUBSEQUENT EVENTS
We have evaluated events or transactions that occurred after the balance sheet date of March 31, 2010 through April 28, 2010, which is the date the financial statements were issued.
On April 7, 2010 we issued a press release and filed a Form 8-K announcing that the NASDAQ Hearing Panel determined to grant the Company’s request for continued listing on The NASDAQ Capital Market subject to the condition that, on or before July 12, 2010, the Company evidence a closing bid price of $1 or more for a minimum of ten consecutive trading days.
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations
COMPANY OVERVIEW
The following discussion and analysis provides information that our management believes is relevant to an assessment and understanding of the results of operations and financial condition of Pro-Dex, Inc. (“Company”, “Pro-Dex”, “we”, “our” or “us”) for each of the three and nine month periods ended March 31, 2010 and 2009, respectively. This discussion should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included elsewhere in this report. This report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear. Our actual future results could differ materially from those discussed herein. Our critical accounting policies relate to revenue recognition, inventory valuation for slow moving items, impairment of goodwill and intangibles, warranty reserves, and recoverability of deferred income taxes.
Except for the historical information contained herein, the matters discussed in this report, including, but not limited to, discussions of our product development plans, business strategies and market factors influencing our results, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation within our target marketplace and among our competitors, and competition from larger, better capitalized competitors. Many other economic, competitive, governmental and technological factors could impact our ability to achieve our goals. You are urged to review the risks, uncertainties and other cautionary language described in this report, as well as in our other public disclosures and reports filed with the Securities and Exchange Commission (“SEC”) from time to time, including, but not limited to, the risks, uncertainties and other cautionary language discussed in our Annual Report on Form 10-K for our fiscal year ended June 30, 2009.
With operations in Irvine, California, Beaverton, Oregon and Carson City, Nevada, we provide power and control products used in medical, aerospace, military, research and industrial applications. Experience in multi-axis motion control, fractional horsepower motors and rotary drive systems allows us to develop products that require high precision in harsh environments.
Our products are found in hospitals, dental offices, medical engineering labs, commercial and military aircraft, scientific research facilities and high-tech manufacturing operations around the world. The names of Micro Motors, Oregon Micro Systems, and Astromec are used for marketing purposes as brand names.
Our principal headquarters are located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number is 949-769-3200. Our Internet address is www.pro-dex.com . Our annual reports on Form 10-K quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports and other SEC filings, are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above. Our filings with the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov and company specific information at www.sec.gov /edgar/searchedgar/companysearch.html.
Critical Accounting Estimates and Judgments
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The significant accounting policies that are believed to be the most critical to fully understanding and evaluating our reported financial results include revenue recognition, warranty reserve, inventory valuations for slow moving items, impairment of goodwill, and the recovery of deferred income tax assets.
16
Revenue Recognition
Revenue on product sales is recognized upon shipment to the customer based on its terms of FOB shipping point, where the risk of loss and title transfer to the customer. We record sales in accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition. Under these guidelines, revenue is recognized when all of the following exist: persuasive evidence that a sale arrangement exists, delivery of the product has occurred, the price is fixed or determinable, and payment is reasonably assured. We sell some of our products with a warranty that provides for repairs or replacement of any defective parts for a period after the sale. At the time of the sale, the Company accrues an estimate of the cost of providing the warranty based on prior experience, but does not accrue an allowance for sales returns. The Company recognizes revenue under research and development agreements as certain deliverables are met as specified in each development contract.
There have been minimal returns for credit, so no reserve for product returns has been established.
Inventory
We determine our inventory value at the lower of cost (first-in, first-out method) or market value. We determine a reduced market value of our inventory based on the aging of inventory on hand. We define “aging of inventory” as inventory that exceeds an estimated 12 months of usage and exceeds orders on hand.
Accounts Receivable
We determine the reserve for our accounts receivable by examining the aging of the receivables. We define “aging of receivables” as time passed since the sale was completed, revenue was recognized and the receivable was established. If the receivable is aged over 90 days old, or has a known collection risk, it is reserved from 10% of its value up to 100%. The actual amount reserved may vary depending on account credit and collection history.
In accordance with Statement of Financial Accounting Standards (“SFAS”), ASC 360 (formerly SFAS No. 144), “Accounting for the Impairment or Disposal for Long-Lived Assets” long-lived assets and intangible assets with definite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit and adverse legal or regulatory developments. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flow over the remaining amortization periods, their carrying values are reduced to estimated fair market value. Estimated fair market value is determined primarily using the anticipated cash flow discounted at a rate commensurate with the risk involved. For the purposes of identifying and measuring impairment, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flow are largely independent of the cash flow of other assets and liabilities.” Our standard annual impairment testing is done April 1 of each year.
We monitor current market conditions and review for potential triggering events quarterly to determine if there is a need for interim impairment testing. We determined that a triggering event for the Astromec and Micro Motors goodwill occurred in the quarter ending December 31, 2009 as a large current customer notified us they were developing a product that would take the place of one that we currently sell them and another customer chose not to enter into a production contract for a product we developed for them. We also determined that a triggering event occurred in the quarter ending December 31, 2009 with the patent intangible asset because no distribution partner or acquirer surfaced since the previous fiscal year end. No triggering event occurred in the quarter ending March 31, 2010.
17
In determining if a triggering event has occurred, we consider not only expectations for growth in the entire US economy, but also expectations for regional growth specific to our sales markets and specific to our industry and product lines. While our operating units are influenced by changes in the general economic outlook of the United States, they are most heavily influenced by changes specific to the medical device industry. Furthermore, the magnitude of economic changes within the industry is viewed alongside the outlooks and forecasts specific to the reporting units to obtain a better sense of the likelihood that goodwill may be impaired. Declines within the industry’s outlook are reflected in the unit’s revenue projections.
We identify two reporting units for purposes of our annual goodwill impairment testing arising from its acquisitions of Micro Motors and Astromec. In accordance with ASC 350 (formerly SFAS No. 142), goodwill is not amortized and is assessed annually for impairment (as of April 1) or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Our Carson City reporting unit corresponds to the operations resulting from the Astromec acquisition, while our Irvine reporting unit corresponds to the operations resulting from the Micro Motors acquisition. Our intangible asset was related to the interosseous patents associated with the “Intraflow” acquisition. We did not test for impairment in the quarter ending March 31, 2010 as no triggering event occurred.
Warranties
The warranty accrual is determined by reviewing the return rates and warranty repair costs for warranty eligible products. We accrue an amount of expected repair cost based on these factors projected for the future applicable warranty period. If actual return rates or repair costs differ from our estimates, actual results could vary from the projected accrual. The repair return rates and cost assumptions are reviewed quarterly.
Property, Plant, Equipment & Leasehold Improvements, Net
Property, plant and equipment is recorded at cost and consists of the following:
Unaudited
Audited
Land
757,000
Building
1,470,000
Leasehold Improvements
2,287,000
2,283,000
Equipment
6,725,000
6,620,000
11,239,000
11,130,000
Accumulated Depreciation
(5,688,000)
(5,149,000)
Total property, pland & equipment, net
Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows: building - 39 years, equipment - - 3 to10 years; and leasehold improvements are depreciated over the shorter of the term of the lease or their estimated useful lives.
Stock-Based Compensation
We are subject to ASC 718 (formerly Statement of Financial Accounting Standards (“SFAS”) No. 123 (R) Accounting for Stock-Based Compensation as revised December 2004.) This standard establishes the accounting standards for equity compensation, and applies to us in the recognition of the cost of stock options awarded based on the grant-date fair value of those awards.
18
Income Taxes
As part of the process of preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves estimating the actual current tax liabilities together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheet. The most significant tax assets are future deductions from the amortization of intangibles over the next ten years, inventory reserves and net operating loss carry forwards. Tax assets also result from net operating losses and research and development tax credits. We must then assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, a valuation allowance must be established. To the extent we establish a valuation allowance or increase or decrease this allowance in a period, the impact will be included in the tax provision in the statement of operations.
Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax asset. Such determination is based primarily on our historical taxable income, with some consideration given to our estimates of future taxable income by jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable. We carry a valuation allowance against our deferred tax assets and changes in this allowance are reflected through income tax expense.
Description of Business
The majority of our revenue is derived from designing, developing and manufacturing rotary drive systems for the medical device and dental industries, motion control software and hardware for industrial and scientific applications and fractional horsepower DC motors for aerospace, medical and military applications. A large part of our revenue has been driven by developing and selling numerous types of private label rotary drive systems for use in dental, cranial, spinal, arthroscopic and orthopedic surgery. Other revenue sources include designing and manufacturing miniature pneumatic motors, fractional horsepower DC motors and motion control systems for industrial applications in the automotive and aerospace industries.
The Company's revenue is derived from five main customer types. The proportion of total sales to each customer type and sales by location are noted in the tables below (unaudited):
Sales by customer type ($'000)
Medical
3,546
58%
2,912
63%
10,324
59%
8,275
53%
Aerospace
964
16%
387
8%
2,403
14%
1,809
12%
Industrial
593
10%
243
5%
1,705
2,054
13%
Dental
508
574
1,527
9%
1,883
Government and other
550
492
11%
1,532
1,480
Total Sales
6,161
100%
4,608
17,491
15,501
The majority of the Irvine-based sales include medical products that utilize proprietary designs developed by us under exclusive design and supply agreements. Our dental products are primarily sold to original equipment manufacturers and dental product distributors. In Beaverton, we design and manufacture embedded multi-axis motion controllers used to regulate the motion of servo and stepper motors, predominantly for the factory automation, scientific research, and medical analysis equipment industries. Our Carson City products include high reliability fractional horsepower DC motors designed for harsh environments, primarily for the aerospace and medical markets.
19
We hold the following three independently verified certifications: ISO 9001:2000, ISO 13485 revised 1998, and Medical Device Directive 93\42\EEC Annex II company.
At the present time, we are generally able to fill orders within 60 days. At March 31, 2010, we had a backlog, including orders for delivery beyond 60 days, of $13.2 million compared with a backlog of $11.6 million at March 31, 2009 and $9.9 million at June 30, 2009. We expect to ship most of our backlog in fiscal year 2010 and the remainder in fiscal year 2011 and 2012. The increased backlog compared to March 2009 and June 2009 is related to orders by our largest customer (see Note 8). We experience some seasonal fluctuations in our new order bookings as increases in our fiscal second quarter orders correspond to new calendar year advance orders from our major customers. We may experience variability in our new order bookings due to the timing of major new product launches and customer planned inventory builds. However, we do not typically experience seasonal fluctuations in our shipments and revenues.
RESULTS OF OPERATIONS
For the Three-Month periods ended March 31, 2010 and 2009
The following table sets forth the periods indicated and the percentage of net revenues represented by each item in our Consolidated Statements of Operations.
(In Thousands)
Net sales:
3,869
3,497
76%
Gross Profit
2,292
37%
1,111
24%
Selling, general and administrative expenses
1,269
21%
1,096
0%
997
22%
614
686
15%
Income (Loss) from Operations
409
7%
(1,668)
-36%
Net interest and other expense
(10)
(56)
-1%
225
4%
1,287
28%
Net income
174
3%
(3,011)
-65%
Net Sales. Consolidated sales increased $1,553,000 to $6,161,000 from $4,608,000 for the quarter ended March 31, 2010 compared to the quarter ended March 31, 2009. The increase was primarily due to a partial recovery from the large downturn in the third quarter of fiscal year 2009. The third quarter of 2009 saw a substantial decrease in industrial motion control sales, as that industry was severely negatively impacted by the economic climate. Aerospace sales were negatively impacted by the timing of deliveries on certain contracts that had lower requirements during the quarter ended March 31, 2009. Finally, the election of a customer to forego commercial production of a product resulted in a $250,000 fee in the quarter ended March 31, 2010.
Although selective price increases and decreases were implemented in response to market conditions, the majority of the sales changes for each product line are due primarily to changes in sales volume, not the effect of price changes.
20
Gross Profit and Gross Profit Percentage of Sales. Our consolidated gross profit for the quarter ended March 31, 2010 increased $1,181,000 or 106% over the same quarter in the previous year due to the higher sales volume and fee. Gross profit as a percentage of sales was 13% higher at 37% for the quarter ended March 31, 2010 compared to 24% for the quarter ended March 31, 2009. Gross profit margins were increased from the same quarter in the previous year due to better facility utilization from the higher sales levels and a favorable sales mix that included additional high margin industrial motion control products. Gross profit and gross profit as a percentage of sales were as follows (unaudited):
Increase
106%
Gross Profit Percentage of Sales
Selling, General and Administrative Costs (S, G&A). Consolidated S, G&A expenses decreased to $1,269,000 for the quarter ended March 31, 2010 from $2,094,000 for the quarter ended March 31, 2009. The decrease in total S, G & A costs was due to the intangible impairment charge ($997,000) during the quarter ending March 31, 2009. The decrease related to the intangible impairment charge was offset by increases in both Selling and General and Administrative expense. The Selling expenses increased due to the ramping up of marketing expenditures ($61,000). G&A expense increased due to higher net severance expense ($68,000) and larger legal expenses ($61,000), which were offset by lower patent amortization cost ($25,000). As a percentage of sales, S, G&A expenses decreased to 21% of sales from 45% of sales for the quarter ended March 31, 2010 and 2009 respectively. The impairment charge accounted for 22% of sales in the quarter ended March 31, 2009. S, G&A costs were as follows (unaudited):
Selling
N/A
General and administrative
782,000
Total S, G&A
1,269,000
2,094,000
-39%
Selling, General & Administrative Percentage of Sales
45%
Research and Development (R&D) Costs. Research and development cost decreased $72,000 to $614,000 for the quarter ended March 31, 2010 from $686,000 for the quarter ended March 31, 2009, a decrease of 10%. The decrease was due mainly to lower labor costs ($73,000). Company-funded research and development costs were as follows (unaudited):
Decrease
Research and Development costs
-10%
R & D Percentage of Sales
Operating Profit and Operating Profit Percentage of Sales. Our resulting consolidated operating profit for the quarter ended March 31, 2010 increased to $409,000 compared to an operating loss of ($1,668,000) for the same quarter in the previous year. Operating profit as a percentage of sales increased to 7% for the quarter ended March 31, 2010 compared to -36% for the quarter ended March 31, 2009. Operating profit and margin were as follows (unaudited):
Operating Profit
Operating Profit Percentage of Sales
21
Royalties and Other Income. We received $40,000 in royalty income in the three months ended March 31, 2010, compared to no royalty income in the quarter ended March 31, 2009. The $40,000 royalty was a one-time final payment ending the royalty obligation. We had no “Other Income” in either period.
Net Interest Expense. Net interest expense for the quarter ended March 31, 2010 was $50,000 compared to $56,000 in the quarter ended March 31, 2009 due to lower debt levels.
Income Tax (Benefit). Our estimated effective combined federal and state tax rate on income from operations for the quarter ended March 31, 2010 resulted in a provision of 56% to earnings before tax compared to a -75% provision to earnings before tax for the quarter ended March 31, 2009. The inflated 2010 rate is due primarily to booking $93,000 in credits last quarter that were freed up for future use and not refunded, which, combined with the realization of alternative minimum tax $131,000 created for the current quarter. The reason for the higher 2009 rate was due to a $1,960,000 valuation allowance against our current and long term deferred tax assets.
Net Income. Our net income for the three months ended March 31, 2010 was $174,000 or $0.02 per share on a basic and diluted basis, as compared to a net loss of $(3,011,000) or $0.31 per share on a basic and diluted basis for the three months ended March 31, 2009.
For the Nine-Month periods ended March 31, 2010 and 2009
17,490
11,324
65%
10,703
69%
6,166
35%
4,798
31%
3,437
20%
3,449
140
1%
6%
1,811
2,083
778
(1,731)
-11%
(110)
(167)
(Benefit) provision for income taxes
(269)
-2%
1,149
937
(3,047)
-20%
Net Sales. Consolidated net sales increased $1,989,000 from $15,501,000 for the nine months ended March 31, 2009 to $17,490,000 for the nine months ended March 31, 2010. The increase was due to the delivery of a newly developed product to a major medical customer which began during the second quarter of fiscal year 2010 and has continued into the third quarter in addition to a 46% increase in revenue from our largest customer. Also, we saw the partial recovery from the economic downturn, especially in motion control sales, in the third quarter of fiscal year 2009. Finally, the election of a customer to forego commercial production of a product resulted in a $250,000 fee in the quarter ended March 31, 2010.
22
Gross Profit and Gross Profit Percentage of Sales. Our consolidated gross profit for the nine months ended March 31, 2010 increased $ 1,368,000 or 29% over the same period in the previous year due to higher sales volume. Gross profit as a percentage of sales was 4% higher at 35% for the nine months ended March 31, 2010, compared to 31% for the same period ended March 31, 2009. Gross profit and gross profit as a percentage of sales were as follows (unaudited):
29%
Selling, General and Administrative Costs (S, G&A). Consolidated S, G&A expenses decreased to $3,577,000 for the nine months ended March 31, 2010 from $4,447,000 for the nine months ended March 31, 2009. S, G&A costs were lower in the first nine months of 2010 compared to the first nine months of 2009 due to the intangible impairment charge ($997,000) during the quarter ending March 31, 2009. The remainder of the unamortized patent related intangible was determined to be impaired during the quarter ended December 31, 2009 and expensed ($140,000). The decrease related to the impairment charge was offset by an increase in Selling expense due to increased headcount ($52,000). General and administrative costs were lower due to reduced consulting expense related to Sarbanes-Oxley compliance ($50,000). As a percentage of sales, S, G&A expenses decreased to 20% of sales from 29% of sales for the nine months ended March 31, 2010 and 2009, respectively. The impairment accounted for 1% and 6% of sales for the nine months ending March 31, 2010 and 2009 respectively. S, G&A costs were as follows (unaudited):
2,462,000
-86%
3,577,000
4,447,000
Research and Development (R&D) Costs. Research and development expenses decreased $272,000 to $1,811,000 for the nine months ended March 31, 2010 from $2,083,000 for the nine months ended March 31, 2009, a decrease of 13%. The decrease was primarily due to decreased labor and related costs ($271,000). Research and development costs were as follows (unaudited):
-13%
Operating Profit (loss) and Operating Profit (loss) Percentage of Sales. Our consolidated operating profit for the nine months ended March 31, 2010 was $778,000 compared to an operating loss of ($1,731,000) for the same period in the previous year. Operating profit as a percentage of sales increased to 4% for the nine months ended March 31, 2010 compared to an operating loss of (11%) for the nine months ended March 31, 2009. Operating profit and margin were as follows (unaudited):
23
Operating Profit (loss)
Royalties and Other Income. We received $44,000 in royalty payments in the nine months ended March 31, 2010, compared to $9,000 in royalty payments in the nine months ended March 31, 2009. $40,000 of the $44,000 in the nine months ended March 31, 2010 was related to a final one-time payment ending the royalty obligation. We had no “Other Income” in either period.
Net Interest Income/Expense. Net interest expense for the nine months ending March 31, 2010 was $154,000 compared to net interest expense of $176,000 in the nine months ended March 31, 2009, due to lower debt balances.
Income Tax (Benefit) Provision. Our estimated effective combined federal and state tax rate on income from operations for the nine months ended March 31, 2010 resulted in a benefit to earnings before tax of 40% compared to a provision of -61% to earnings before tax for the nine months ended March 31, 2009. The difference in the 2009 rate is due primarily to the realization of a portion of the Company's deferred tax asset for the federal net operating loss carryover generated in the year ended June 30, 2009. Federal legislation enacted on November 6, 2009 provided for a five year carry back of certain NOLs. The reason for the inflated 2009 rate was due to a $1,960,000 valuation allowance against our current and long term deferred tax assets.
Net Income/Loss. Our net income for the nine months ended March 31, 2010 was $937,000 or $0.10 per share, as compared to a loss of $3,047,000 or $0.31 per share on a basic and diluted basis for the nine months ended March 31, 2009.
Liquidity and Capital Resources
The following table presents selected financial information as of the end of the third quarter of fiscal 2010 and 2009, respectively, as well as of the year ended June 30, 2009:
As of March 31,
As of
Working Capital¹
5,842,000
4,264,000
4,548,000
Credit Line outstanding balance
0
Net (Cash) Debt³
(349,000)
3,465,000
2,204,000
Tangible book value/common share²
0.87
0.73
0.76
Number of days of sales outstanding (DSO) in
accounts receivable at end of quarter4
41
40
1 Working Capital = Ending Current Assets less Ending Current Liabilities.
2 Tangible book value/common share = (Total shareholders’ equity – Net intangible asset (patents) - Goodwill) / (basic outstanding shares).
3 Net (Cash) Debt = Total Ending Long Term plus Current Portion of Debt plus Credit Line less Cash
4 DSO = Ending Net Accounts Receivable balance / (Previous Quarter Sales / 91).
24
Our working capital at March 31, 2010 increased to $5.8 million compared to $4.3 million at March 31, 2009 and was $1.3 million higher than the $4.5 million at June 30, 2009. Cash flow provided by operations was $2,661,000 during the nine months ended March 31, 2010 compared to cash flow provided by operations of $840,000 during the nine months ended March 31, 2009. Fiscal year 2010 cash increased mainly because of increased profitability combined with increases in accrued expenses and decreases in inventory offset by an increase in trade accounts receivable.
During the quarter ended December 31, 2010 one of our largest customers (the “Customer”) informed us they are in the process of developing, and plan to eventually manufacture their own surgical hand pieces which are functionally comparable to the two products currently provided by the Company. Pro-Dex has been the exclusive manufacturer of these products since they were developed.
The Company intends to find additional business and reduce its operating costs as necessary to minimize the impact of a potential revenue reduction. In the event that the Customer's future purchases are reduced beyond the amount of any additional business won and any cost savings realized, the Company is likely to experience a material and adverse impact on its business and revenue
25
At March 31, 2010, we had cash and cash equivalents of $3,352,000. We believe that our cash and cash equivalents on hand, together with cash flows from operations, if any, and amounts available under the credit facilities will be sufficient to meet our working capital and capital expenditure requirements for this and the next year.
In September 2002, our Board of Directors authorized the repurchase on the open market of up to 500,000 shares of our outstanding common stock at a share price no greater than $1.25, subject to compliance with applicable laws and regulations. There is no requirement that we repurchase all or any portion of such shares. The maximum total value of the repurchase is not to exceed $500,000. Since the initiation of the buyback program in 2002 through March 31, 2010, we have repurchased 295,395 shares for $177,213 at an average price of $0.60 per share. Our Board suspended the buyback authorization in May 2009 and has not set a reinitiation date for the purchase of our shares pursuant to this program.
Not applicable.
The Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Based on that evaluation for the quarter ended March 31, 2010, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated, recorded, processed, summarized and reported to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, and to allow timely decisions regarding whether or not disclosure is required.
During the quarter ended March 31, 2010, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
PART II
OTHER INFORMATION
Item 1A. Risk Factors.
Except as noted below, there have been no material changes to the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for our fiscal year ended June 30, 2009. In addition to the information below and the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K, which could materially affect our business, financial condition and future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or operating results.
Our common stock could be delisted from NASDAQ, which could have a material adverse effect on the price of our common stock.
We have previously disclosed that our common stock would be subject to delisting from the NASDAQ Capital Market after January 7, 2010 if our common stock did not meet the $1.00 minimum bid price requirement set forth in NASDAQ’s Listing Rule 5550(a)(2) by that date. On January 11, 2010, the NASDAQ Staff notified us that our common stock was subject to delisting for failing to comply with the minimum bid price requirement. In accordance with the Listing Rules, we requested an oral hearing before a NASDAQ Listing Qualification Panel (“Panel”), which automatically stayed the delisting of our common stock pending the issuance of the Panel’s decision after the hearing. Based on our hearing, the Panel has determined to grant our request for continued listing on the NASDAQ Capital Market subject to the condition that, on or before July 12, 2010, our common stock achieves a closing bid price of $1.00 or more for a minimum of ten consecutive trading days. However, there can be no assurances that our common stock will achieve the minimum bid price requirement by July 12, 2010 or that our other efforts to maintain the listing of our common stock on NASDAQ will be successful.
If our common stock is delisted from the NASDAQ Capital Market, then the market liquidity for our common stock would likely be negatively affected, which would likely have a material adverse effect on the price of our common stock.
A substantial portion of our revenue is derived from a small number of customers such that if we were to lose one, it could have a material and adverse effect on our business, financial condition and results of operations.
We have few significant customers that contribute a significant portion of our revenue. Our loss of one or more of such customers could severely impact us, including a material adverse effect on our business, financial condition, cash flows, revenue and results of operations.
In December, 2010 one of our largest customers (the “Customer”) informed us they are in the process of developing, and plan to eventually manufacture their own surgical hand pieces which are functionally comparable to the two products currently provided by the Company. Pro-Dex has been the exclusive manufacturer of these products since they were developed.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
Item 5. Other Information.
Item 6. Exhibits.
Certifications of Chief Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certifications of Chief Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
SIGNATURES
In accordance with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: April 29, 2010
PRO-DEX INC.
By: / s / Mark Murphy
By: / s / Jeffrey J. Ritchey
Mark Murphy
Jeffrey J. Ritchey
Chief Executive Officer
Secretary and Chief Financial Officer
(Principal Financial and Accounting Officer)
End of Filing